Delving into the Thyrointegrin Antagonist & Cancer Therapeutics
Time: 3:40 pm
day: Day One
Details:
- Considering the challenges in developing novel strategies and the failure of previous avb3 antagonists in cancer therapy
- Pinpoint the problems with these in order to re-assess the MoAs
- Overcome these challenges to design novel therapeutics
